Cargando…
A novel gene signature unveils three distinct immune-metabolic rewiring patterns conserved across diverse tumor types and associated with outcomes
Existing immune signatures and tumor mutational burden have only modest predictive capacity for the efficacy of immune check point inhibitors. In this study, we developed an immune-metabolic signature suitable for personalized ICI therapies. A classifier using an immune-metabolic signature (IMMETCOL...
Autores principales: | Pedrosa, Leire, Foguet, Carles, Oliveres, Helena, Archilla, Iván, de Herreros, Marta García, Rodríguez, Adela, Postigo, Antonio, Benítez-Ribas, Daniel, Camps, Jordi, Cuatrecasas, Miriam, Castells, Antoni, Prat, Aleix, Thomson, Timothy M., Maurel, Joan, Cascante, Marta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9479210/ https://www.ncbi.nlm.nih.gov/pubmed/36119118 http://dx.doi.org/10.3389/fimmu.2022.926304 |
Ejemplares similares
-
Mutational Status of SMAD4 and FBXW7 Affects Clinical Outcome in TP53–Mutated Metastatic Colorectal Cancer
por: Lahoz, Sara, et al.
Publicado: (2022) -
A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
por: Español-Rego, Marta, et al.
Publicado: (2022) -
Genome-scale integration of transcriptome and metabolome unveils squalene synthase and dihydrofolate reductase as targets against AML cells resistant to chemotherapy
por: Karakitsou, Effrosyni, et al.
Publicado: (2021) -
The EMT factor ZEB1 paradoxically inhibits EMT in BRAF-mutant carcinomas
por: Sánchez-Tilló, Ester, et al.
Publicado: (2023) -
Genome Scale Modeling to Study the Metabolic Competition between Cells in the Tumor Microenvironment
por: Frades, Itziar, et al.
Publicado: (2021)